Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 29, 2013
Event: Entry into a Second Amended and Restated Revolving Credit Agreement.
Key Financial Metrics and Debt Structure
This filing details a restructuring of the Company's credit facility rather than reporting operational financial results (revenue, profit, or cash flow). The new agreement establishes the following debt structure:
- Total Facility Capacity: Up to $50 million aggregate principal amount.
- Term Loan: $15 million (conversion of existing revolving advances); Maturity: March 29, 2018.
- Revolving Line: Maximum $25 million; Maturity: March 29, 2016.
- Delayed Draw Term Loan (DDTL): Up to $15 million to fund capital contributions to subsidiary Harvard Apparatus Regenerative Technology, Inc. (HART); Maturity: March 29, 2018.
- Interest Rates:
- Term Loan and DDTL: LIBOR + 3.0% margin.
- Revolving Line: LIBOR + 2.5% margin.
- Collateral: Secured by substantially all assets of the Company and its domestic subsidiaries (excluding HART).
Material Changes Versus Prior Period
The Company amended and restated its previous credit agreement dated August 7, 2009. The primary material changes include:
- Conversion of existing outstanding revolving advances into a fixed $15 million Term Loan.
- Establishment of a new $15 million Delayed Draw Term Loan specifically for funding the HART subsidiary.
- Requirement to fix interest rates on at least 50% of the Term Loan and DDTL via interest rate swaps.
Guidance, Risks, and Covenants
Financial Covenants: The agreement imposes restrictive covenants requiring the Company to maintain specific consolidated financial ratios, including:
- Maximum leverage ratio.
- Minimum fixed charge coverage ratio.
- Minimum working capital.
Risks and Contingencies:
- Default Events: Failure to comply with covenants, breach of representations, payment defaults, or insolvency may allow the Administrative Agent to declare all amounts immediately due and payable.
- Prepayment: Allowed at any time during the loan terms.
- Representations: The filing notes that representations and warranties are subject to contractual materiality standards and risk allocation, which may differ from shareholder materiality standards.
Management Commentary: The filing does not provide specific management commentary on future operational outlook beyond the terms of the credit agreement.
Investor Verification Checklist
- Verify the current outstanding balance of the $15 million Term Loan and any drawdowns on the $25 million Revolving Line.
- Confirm the Company's compliance with the new financial covenants (leverage, fixed charge coverage, working capital) in subsequent quarterly reports.
- Review the status of the $15 million DDTL drawdown for the HART subsidiary capital contribution.
- Examine the Company's hedging strategy for the required 50% interest rate swap on the Term Loan and DDTL.
- Check for any subsequent amendments or waivers regarding the restrictive covenants.